OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)

Autor: M Chaparro, M García Donday, S Riestra, A J Lucendo, J M Benítez, M Navarro-Llavat, J Barrio, V J Morales-Alvarado, M Rivero, D Busquets, E Leo Carnerero, O Merino Ochoa, O Nantes Castillejo, P Navarro, M Van Domselaar, A Gutiérrez Casbas, I Alonso-Abreu, R Mejuto, L Fernández Salazar, M Iborra, M D Martín-Arranz, J R Pineda, M J Sampedro, K Serra Nilsson, A Bouhmidi Assakali, L Batista, C Muñoz Villafranca, I Rodríguez-Lago, D S Ceballos Santos, I Guerra, M Mañosa, I Marín Jimenez, I Vera Mendoza, M Barreiro-de Acosta, E Domènech, M Esteve, V García-Sánchez, P Nos, J Panés, J P Gisbert

Publikováno v: Journal of Crohn's and Colitis. 17:i50-i54

Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven in clinical trials including patients in clinical, endoscopic, and radiologic remission at the time of anti-TNF withdrawal to make r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8acd9ed996ae8e4fcd0df9c8a1758fb8
https://doi.org/10.1093/ecco-jcc/jjac190.0037

P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU

Autor: M Chaparro, A Gutiérrez, C Calviño-Suárez, J M Huguet, M Calvo, M Aguas, R Camargo Camero, M Á de Jorge Turrión, D Hervías Cruz, P López Serrano, S Marín Pedrosa, P Martínez Montiel, M Rivero, R Vicente Lidón, L Arias García, M Arroyo, L Bujanda, M J Casanova, M Figueiras, A J Lucendo, N Manceñido Marcos, L Márquez, M D Martín-Arranz, M Boscá Watts, Y Ber, P Ramírez de la Piscina Urraca, I Pérez-Martínez, V Robles, A Ruiz-Cerulla, J M Vázquez Morón, L Madero, M Barreiro-de Acosta, M Capilla, I Vera Mendoza, D Acosta, Y Brenes, S Hermida, P Parra, M G Donday, J P Gisbert

Publikováno v: Journal of Crohn's and Colitis. 16:i491-i493

Background The safety of ustekinumab in pregnant patients with inflammatory bowel disease (IBD) and in their offspring has been barely studied. Aims Primary: To know the risk of serious adverse events (SAEs) in women exposed to ustekinumab during pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::937c68b486a568e6c69c84324094d726
https://doi.org/10.1093/ecco-jcc/jjab232.672

P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients

Autor: M I Iborra Colomino, R Ferreiro-Iglesias, M D Martín-Arranz, F Mesonero-Gismero, A Mínguez, S Porto Silva, L García-Ramírez, I García de la Filia, G Bastida, L Nieto García, C Suárez Ferrer, M Aguas, M Barreiro de Acosta, P Nos

Publikováno v: Journal of Crohn's and Colitis. 17:i629-i630

Background Ustekinumab has been recently approved for the treatment of moderately to severe ulcerative colitis (UC). Data from the UNIFI clinical trial are encouraging; nevertheless, real-world assessment is needed. We assess the effectiveness, safet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3ddcb8c8da0d112c6a6f9fc91c90147
https://doi.org/10.1093/ecco-jcc/jjac190.0630

Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study

Autor: M. Sancho, Begoña Vieites, M. D. Martín-Salvago, L. Alfaro, María Ángeles López-García, L. López-Vilaró, B. Fernández-Rodriguez, F. Villardell, Octavio Burgues, V. Peg, C.L. Ramirez-Tortosa, R. Rezola

Publikováno v: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
CLINICAL & TRANSLATIONAL ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Scientia

Objective To evaluate the predictive and prognostic value of total tumor load (TTL) in sentinel lymph nodes (SLNs) in patients with infiltrating breast cancer after neoadjuvant systemic therapy (NST). Methods This retrospective multicenter study used

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b16877839597721496f22a361781fb8c
https://doi.org/10.1007/s12094-020-02530-4

P360 Role of intestinal ultrasound scores in the diagnosis of post-operative recurrence in Crohn's disease

Autor: C Amor Costa, C Suárez Ferrer, J Poza Cordón, J Yebra Carmona, J L Rueda García, M Sánchez Azofra, E Martín Arranz, I González Díaz, C Amiama Roig, M D Martín Arranz

Publikováno v: Journal of Crohn's and Colitis. 17:i494-i494

Background Ileocolonoscopy is the gold standard to evaluate post-operative recurrence (POR) in Crohn's disease (CD) patients. Rutgeerts endoscopic score remains the gold standard in the evaluation of post-operative recurrence in CD. Intestinal ultras

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4b725fd72b17ab3acc5e27b660c09f1d
https://doi.org/10.1093/ecco-jcc/jjac190.0490